Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster... Show more
LAB saw its Momentum Indicator move above the 0 level on April 11, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .
LAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Aroon Indicator for LAB entered a downward trend on March 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.869) is normal, around the industry mean (23.907). P/E Ratio (0.000) is within average values for comparable stocks, (81.831). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.010) is also within normal values, averaging (42.115).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
a manufacturer of integrated fluidic circuit systems
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, LAB has been loosely correlated with CERS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LAB jumps, then CERS could also see price increases.
Ticker / NAME | Correlation To LAB | 1D Price Change % | ||
---|---|---|---|---|
LAB | 100% | N/A | ||
CERS - LAB | 49% Loosely correlated | -2.21% | ||
ATEC - LAB | 46% Loosely correlated | -2.65% | ||
SIBN - LAB | 43% Loosely correlated | -2.32% | ||
MXCT - LAB | 40% Loosely correlated | +1.92% | ||
BLFS - LAB | 40% Loosely correlated | +1.59% | ||
More |